BioCentury
ARTICLE | Clinical News

Aerie rebounds after FDA clears IOP endpoint

June 17, 2015 1:01 AM UTC

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) gained $6.64 (50%) to $19.91 on Tuesday after it said FDA will allow the company to change the primary endpoint of the Phase III Rocket 2 trial of glaucoma treatment Rhopressa ( AR-13324).

The new endpoint is non-inferiority to the adrenergic receptor beta ( ADRB) blocker timolol in lowering intraocular pressure in patients with glaucoma or ocular hypertension whose IOP is between 20 and 25 mmHg. The study's previous primary endpoint, non-inferiority to timolol among patients in the 20-27 mmHg range, will be a secondary endpoint. FDA did not require a change in the study's p value. ...